CO2019014831A2 - Nuevas formulaciones orales de belinostat - Google Patents

Nuevas formulaciones orales de belinostat

Info

Publication number
CO2019014831A2
CO2019014831A2 CONC2019/0014831A CO2019014831A CO2019014831A2 CO 2019014831 A2 CO2019014831 A2 CO 2019014831A2 CO 2019014831 A CO2019014831 A CO 2019014831A CO 2019014831 A2 CO2019014831 A2 CO 2019014831A2
Authority
CO
Colombia
Prior art keywords
belinostat
oral formulations
new oral
new
formulations
Prior art date
Application number
CONC2019/0014831A
Other languages
English (en)
Inventor
Perrine Pivette
Caroline Lemarchand
Ian Yates
Corey Bloom
Original Assignee
Onxeo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/067717 external-priority patent/WO2019002614A1/en
Application filed by Onxeo filed Critical Onxeo
Publication of CO2019014831A2 publication Critical patent/CO2019014831A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere a nuevas formulaciones de belinostat adecuadas para administración oral, su proceso de preparación, las composiciones farmacéuticas que comprenden dichas formulaciones y sus usos.
CONC2019/0014831A 2017-06-30 2019-12-27 Nuevas formulaciones orales de belinostat CO2019014831A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527684P 2017-06-30 2017-06-30
EP17305853 2017-07-03
PCT/EP2018/067717 WO2019002614A1 (en) 2017-06-30 2018-06-29 NEW ORAL FORMULATIONS OF BELINOSTAT

Publications (1)

Publication Number Publication Date
CO2019014831A2 true CO2019014831A2 (es) 2020-04-24

Family

ID=62816549

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0014831A CO2019014831A2 (es) 2017-06-30 2019-12-27 Nuevas formulaciones orales de belinostat

Country Status (21)

Country Link
US (1) US11266614B2 (es)
EP (1) EP3644970B8 (es)
JP (1) JP7247122B2 (es)
CN (1) CN110996913A (es)
AU (1) AU2018294561B2 (es)
BR (1) BR112019028088A8 (es)
CA (1) CA3067723A1 (es)
CL (1) CL2019003801A1 (es)
CO (1) CO2019014831A2 (es)
DK (1) DK3644970T3 (es)
EC (1) ECSP19091293A (es)
ES (1) ES2909583T3 (es)
HR (1) HRP20220309T1 (es)
HU (1) HUE057999T2 (es)
IL (1) IL271658B2 (es)
LT (1) LT3644970T (es)
MX (1) MX2019015869A (es)
PL (1) PL3644970T3 (es)
RS (1) RS63046B1 (es)
SI (1) SI3644970T1 (es)
ZA (1) ZA201908532B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2967689T3 (es) * 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1469829B1 (en) * 2002-02-01 2016-01-27 Bend Research, Inc Immediate release dosage forms containing solid drug dispersions
AU2012213940B2 (en) * 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
EP2494969B1 (en) 2005-05-13 2015-03-25 TopoTarget UK Limited Pharmaceutical formulations of HDAC inhibitors
JP2007045788A (ja) 2005-08-12 2007-02-22 Kenjiro Koga グリチルリチン酸高濃度水溶液の調製法
AU2006313517B2 (en) 2005-11-10 2013-06-27 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2011064663A1 (en) * 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
EP2572731A1 (en) 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
US9114170B2 (en) * 2012-11-08 2015-08-25 Isp Investments Inc. Highly loaded amorphous efavirenz composition and process for preparing the same
EP3137086A4 (en) 2014-05-02 2017-12-27 Oncoethix GmbH Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
BR112017002231A2 (pt) 2014-08-07 2018-07-17 Pharmacyclics Llc novas formulações de um inibidor de tirosina cinase de bruton
US11439643B2 (en) 2015-06-16 2022-09-13 Acrotech Biopharma Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma
JP2017095428A (ja) 2015-11-27 2017-06-01 国立大学法人神戸大学 脂質代謝改善剤
WO2018029699A1 (en) * 2016-08-11 2018-02-15 Msn Research & Development Center Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof

Also Published As

Publication number Publication date
AU2018294561B2 (en) 2023-12-07
BR112019028088A8 (pt) 2022-11-08
IL271658B2 (en) 2023-09-01
ZA201908532B (en) 2022-07-27
JP7247122B2 (ja) 2023-03-28
ES2909583T3 (es) 2022-05-09
CA3067723A1 (en) 2019-01-03
LT3644970T (lt) 2022-04-25
RS63046B1 (sr) 2022-04-29
MX2019015869A (es) 2020-08-06
PL3644970T3 (pl) 2022-04-25
AU2018294561A1 (en) 2020-01-16
IL271658A (en) 2020-02-27
ECSP19091293A (es) 2020-05-29
EP3644970A1 (en) 2020-05-06
JP2020525499A (ja) 2020-08-27
SI3644970T1 (sl) 2022-05-31
EP3644970B8 (en) 2022-03-16
US20200155485A1 (en) 2020-05-21
BR112019028088A2 (pt) 2020-07-28
EP3644970B1 (en) 2022-02-09
CL2019003801A1 (es) 2020-09-11
IL271658B1 (en) 2023-05-01
CN110996913A (zh) 2020-04-10
HRP20220309T1 (hr) 2022-05-13
HUE057999T2 (hu) 2022-06-28
DK3644970T3 (da) 2022-03-14
US11266614B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
BR112018006243A2 (pt) formas de cristal de mononucleotídeo de beta-nicotinamida
ECSP18014922A (es) Composiciones de insulina de rápida acción
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP13012368A (es) Composiciones farmacéuticas de co-cristales de tramadol y coxibs
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
CL2018001742A1 (es) Compuestos indolinones y sus usos en el tratamiento de enfermedades fibroticas.
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
CU20210077A7 (es) Extractos bacterianos estables como fármacos
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CO2019014831A2 (es) Nuevas formulaciones orales de belinostat
CO2019000083A2 (es) Composiciones farmacéuticas
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
BR112017009848A2 (pt) combinação, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica.
MX2020004675A (es) Formulaciones de alcohol de seda.
CO2017004382A2 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
EA201992844A1 (ru) Новые пероральные составы на основе белиностата